ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00545090

Enrollment

561

Registered

2007-10-17

Start date

2006-08-31

Completion date

2008-06-30

Last updated

2016-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Menopausal Osteoporosis

Brief summary

This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study. All patients completing 6 months in ML19930 will continue to receive Bonviva (150mg po, monthly) for an additional 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

Interventions

DRUGibandronate [Bonviva/Boniva]

150mg po monthly for 6 months

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

No minimum to 85 Years

Healthy volunteers

Inclusion criteria

* patients responding to oral monthly Bonviva during the BonAdAsia study; * willing to continue Bonviva treatment for a further 6 months.

Exclusion criteria

* none specified.

Design outcomes

Primary

Measure	Time frame
SAEs, AEs including fractures, adherence to treatment, clinical improvement, osteoporosis symptoms	Throughout study

Countries

Hong Kong, Indonesia, Philippines, Taiwan, Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026